MedPath

JOYCE TENG

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Early Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (100.0%)

Topical Simvastatin for Treating Infantile Hemangioma

Early Phase 1
Not yet recruiting
Conditions
Hemangioma Skin
Interventions
First Posted Date
2024-02-22
Last Posted Date
2024-02-22
Lead Sponsor
Joyce Teng
Target Recruit Count
12
Registration Number
NCT06273111
Locations
🇺🇸

Stanford University, Palo Alto, California, United States

Computational Drug Repurposing for All EBS Cases

Recruiting
Conditions
Healthy
Epidermolysis Bullosa
Epidermolysis Bullosa Simplex
Genetic Skin Disease
Epidermolysis Bullosa Dystrophica
Epidermolysis Bullosa, Junctional
First Posted Date
2017-08-31
Last Posted Date
2024-02-13
Lead Sponsor
Joyce Teng
Target Recruit Count
60
Registration Number
NCT03269474
Locations
🇺🇸

Pediatric Dermatology Clinic at Stanford Children's Hospital, Palo Alto, California, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath